RecruitingPhase 3NCT07566156

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )

Studying Medullary thyroid carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Astellas Pharma Global Development, Inc.
Principal Investigator
Zejing Wang, MD/PhD
Pfizer
Intervention
Enfortumab vedotin(drug)
Enrollment
390 enrolled
Eligibility
18 years · All sexes
Timeline
2026 – 2032

Study locations (1)

Collaborators

Pfizer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07566156 on ClinicalTrials.gov

Other trials for Medullary thyroid carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Medullary thyroid carcinoma →

← Back to all trials